EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 162 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $264,919 | +131048.0% | 9,338 | +35.0% | 0.00% | 0.0% |
| Q4 2022 | $202 | -99.9% | 6,916 | -9.6% | 0.00% | 0.0% |
| Q3 2022 | $202,000 | -43.9% | 7,648 | -5.6% | 0.00% | -50.0% |
| Q2 2022 | $360,000 | -9.8% | 8,100 | +0.5% | 0.01% | +20.0% |
| Q1 2022 | $399,000 | -4.3% | 8,057 | -1.6% | 0.01% | 0.0% |
| Q4 2021 | $417,000 | -12.4% | 8,192 | -3.9% | 0.01% | -16.7% |
| Q3 2021 | $476,000 | +28.0% | 8,526 | -1.9% | 0.01% | +50.0% |
| Q2 2021 | $372,000 | +2.8% | 8,695 | +0.4% | 0.00% | 0.0% |
| Q1 2021 | $362,000 | -16.6% | 8,664 | -7.0% | 0.00% | -20.0% |
| Q4 2020 | $434,000 | -9.6% | 9,312 | -17.6% | 0.01% | -16.7% |
| Q3 2020 | $480,000 | +25.0% | 11,304 | +41.3% | 0.01% | 0.0% |
| Q2 2020 | $384,000 | -2.0% | 8,001 | -6.2% | 0.01% | -14.3% |
| Q1 2020 | $392,000 | -5.8% | 8,527 | +23.2% | 0.01% | +16.7% |
| Q4 2019 | $416,000 | +6.9% | 6,920 | +0.5% | 0.01% | 0.0% |
| Q3 2019 | $389,000 | 0.0% | 6,884 | -1.6% | 0.01% | 0.0% |
| Q2 2019 | $389,000 | +10.2% | 6,993 | -0.0% | 0.01% | 0.0% |
| Q1 2019 | $353,000 | +21.7% | 6,996 | -2.8% | 0.01% | +20.0% |
| Q4 2018 | $290,000 | -40.3% | 7,197 | +2.7% | 0.01% | -28.6% |
| Q3 2018 | $486,000 | +19.7% | 7,010 | +30.5% | 0.01% | +16.7% |
| Q2 2018 | $406,000 | +39.5% | 5,372 | -2.9% | 0.01% | +50.0% |
| Q1 2018 | $291,000 | -3.6% | 5,532 | -2.1% | 0.00% | 0.0% |
| Q4 2017 | $302,000 | -18.6% | 5,649 | -9.3% | 0.00% | -20.0% |
| Q3 2017 | $371,000 | -17.4% | 6,225 | +9.3% | 0.01% | -16.7% |
| Q2 2017 | $449,000 | -7.8% | 5,696 | -2.9% | 0.01% | 0.0% |
| Q1 2017 | $487,000 | +6.8% | 5,867 | +2.2% | 0.01% | 0.0% |
| Q4 2016 | $456,000 | +7.3% | 5,742 | -5.5% | 0.01% | 0.0% |
| Q3 2016 | $425,000 | – | 6,075 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |